Descriptors
Classification > Q - SCIENCE / PRECLINICAL SCIENCES > QV - PHARMACOLOGY > QV 736 Drug industry. Economics of pharmacy. Advertising
QV 736 Drug industry. Economics of pharmacy. Advertising |
Documents disponibles dans cette catégorie (41)
Add the result to your basket Make a suggestion Refine your search Apply to external sources
Extend search on down-posting(s)
Scénarios futurs pour le développement des médicaments et la fixation de leurs prix / Philippe Vandenbroeck / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
Scénarios futurs pour le développement des médicaments et la fixation de leurs prix [printed text] / Philippe Vandenbroeck, Author ; Peter Raeymakers, Author ; Rachel Wickert, Author ; Kim Becher, Author ; Jo Goossens, Author ; Irina Cleemput , Author ; Frank Hulstaert, Author ; Lydia de Heij, Author ; Raf Mertens , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre : Diemen : Zorginstituut Nederland, 2016 . - 21 p. : ill., ; A4.
ISSN : D/2016/10.273/57 : € 0,00
Languages : French (fre)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2013-03 ; Drug Approval ; Economics, Pharmaceutical ; Legislation, Drug ; R271Link for e-copy: https://kce.fgov.be/sites/default/files/2021-11/drugpricing_FR_D30-06.pdf Format of e-copy: PDF (2,9 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3877 Selling sickness / Ray Moynihan / New York, NY : Nation Books (2005)
Selling sickness : how the world's biggest pharmaceutical companies are turning us all into patients [printed text] / Ray Moynihan ; Alan Cassels . - New York, NY : Nation Books, 2005 . - xviii, 254 p. ; 22 cm.
ISBN : 978-1-56025-697-7 : € 19,58
Languages : English (eng)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
Drug Industry ; Health Care ; Health Services Misuse ; Marketing ; Public Health ; Sociology, Medical ; United States ; United States Food and Drug AdministrationAbstract: A controversial and provocative look at the way pharmaceutical companies are helping to create and market illness.
Using their dominating influence in the world of medical science, drug companies are working to widen the very boundaries that define illness. Mild problems are redefined as serious illness, and common complaints are labeled as medical conditions requiring drug treatments. Runny noses are now allergic rhinitis, pms has become a psychiatric disorder, and hyperactive children have add.
Selling Sickness reveals how expanding the boundaries of illness and lowering the threshold for treatments is creating millions of new patients and billions in new profits, in turn threatening to bankrupt national healthcare systems all over the world. This Canadian edition includes an introduction placing the issue in a Canadian context and describing why Canadians should be concerned about the problem.Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=744 Hold
Place a hold on this item
Copies(1)
Barcode Call number Media type Location Section Status 10273-00865 QV 736/MOY Book KCE Library (10.124) Due for return by 07/02/2018 Readers who borrowed this document also borrowed:
TNM Classification of malignant tumours Brierley, James, Gospodarowicz, M. K., Wittekind, Ch Using Patient Reported Outcomes to Improve Health Care Appleby, John Het leven loopt op wieltjes Heselmans, Annemie Redefining health care Porter, Michael E. Geographic variations in health care Geestelijke gezondheidszorg voor kinderen en jongeren Vandenbroeck, Philippe Geestelijke gezondheidszorg voor kinderen en jongeren Vandenbroeck, Philippe Introduction to meta-analysis Borenstein, Michael Les unités neurovasculaires Michiels, Dominik L'économie de la santé pour non économistes Annemans, Lieven Cochrane Handbook for Systematic Reviews of Interventions Higgins, Julian PT Le système du prix de référence et les différences socio-économiques dans l’utilisation des médicaments moins onéreux / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
Le système du prix de référence et les différences socio-économiques dans l’utilisation des médicaments moins onéreux [printed text] / France Vrijens , Author ; Carine Van de Voorde, Author ; Maria-Isabel Farfan-Portet, Author ; Maïté le Polain, Author ; Olivier Lohest, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - X, 69 p. : ill. ; A4. - (KCE Reports B. Health Services Research (HSR); 126B) .
ISSN : D/2010/10.273/19 : 0 €.
Etude nr 2008-08
Languages : English (eng) French (fre)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2008-08 ; Cost-sharing ; Drugs, Generic ; Population Characteristics ; Prescriptions, Drug ; R126 ; Reimbursement Mechanisms ; Socioeconomic FactorsAbstract: Le Centre fédéral d’expertise des soins de santé (KCE) a vérifié si tous les Belges, quel que soit leur statut socio-économique, profitent des avantages financiers que procure l’utilisation de médicaments génériques ou de certains médicaments originaux qui ont baissé leur prix. Le résultat de l’étude est encourageant car ce sont justement les Belges les moins favorisés qui s’avèrent utiliser un peu plus de tels médicaments. Il y aurait tout de même encore moyen de faire mieux, en appliquant des mesures qui encouragent les médecins et les pharmaciens à plus prescrire et délivrer des médicaments moins onéreux. Les patients aussi pourraient recevoir plus d’information sur les suppléments qu’ils paient à l’achat de médicaments pour lesquels une alternative meilleur marché existe. Contents note: Table of contents -- LIST OF ABRREVIATIONS 3 -- GLOSSARY 4 -- 1 INTRODUCTION AND RESEARCH QUESTIONS 7 -- 1.1 BACKGROUND 7 -- 1.2 RESEARCH QUESTIONS AND SCOPE 8 -- 1.3 CONTENT OF THIS REPORT 8 -- 2 INTERNATIONAL COMPARISON OF REFERENCE PRICING 9 -- 2.1 INTRODUCTION 9 -- 2.2 GENERAL DESCRIPTION OF THE REFERENCE PRICE SYSTEM 10 -- 2.2.1 Definition 10 -- 2.2.2 General characteristics of a reference price system 11 -- 2.3 OVERVIEW OF THE REFERENCE PRICE SYSTEM IN A SELECTION OF 11 OECD -- COUNTRIES 13 -- 2.3.1 Methods 13 -- 2.3.2 Definition and scope of the cluster 14 -- 2.3.3 The reference price level 16 -- 2.3.4 Measures for physicians, pharmacists and patients 16 -- 2.4 DESCRIPTION OF THE BELGIAN REFERENCE PRICE SYSTEM 18 -- 2.4.1 Evolution of the legal basis of the RPS 19 -- 2.4.2 Definition and scope of the cluster 21 -- 2.4.3 The reference price level 21 -- 2.4.4 The security margin 23 -- 2.4.5 Exemptions 23 -- 2.4.6 Measures for physicians, pharmacists and patients 23 -- 3 IMPACT OF THE REFERENCE PRICE SYSTEM: A LITERATURE REVIEW 28 -- 3.1 INTRODUCTION 28 -- 3.2 METHODS 28 -- 3.3 RESULTS 29 -- 3.3.1 Search strategy and study selection of the review studies on the impact of a RPS 29 -- 3.3.2 Association of the RPS with drug use 30 -- 3.3.3 Association of the RPS with drug prices 30 -- 3.3.4 Association of the RPS with drug expenditures 30 -- 3.3.5 Association of the RPS with health services use and health 31 -- 4 RESULTS FROM THE ANALYSIS OF BELGIAN PRESCRIPTION DATA IN 2008 32 -- 4.1 INTRODUCTION 32 -- 4.2 THE BELGIAN PHARMACEUTICAL MARKET: EVOLUTION OF MARKET SHARES AND -- OUT-OF-POCKET PAYMENTS 33 -- 4.2.1 Evolution of market shares 33 -- 4.2.2 The reference supplement in 2008 36 -- 4.3 IMPACT OF THE REFERENCE PRICE SYSTEM IN BELGIUM: LITERATURE REVIEW 39 -- 4.3.1 Market share of low cost drugs 39 -- 4.3.2 Expenditures for the NIHDI and for patients 39 -- 4.3.3 Potential gains from the increasing use of low cost drugs 39 -- 4.3.4 Strategies by pharmaceutical firms 40 -- 4.4 METHODS 40 -- 4.4.1 Data sources 40 -- 4.4.2 Time period 41 -- 4.4.3 Selection of data (sampling procedure) 41 -- 4.4.4 Coupling procedure and authorisation from the Privacy Commission 41 -- 4.4.5 Selection and construction of socioeconomic variables 41 -- 4.4.6 Selection of patients and of pharmaceutical products 43 -- 4.4.7 Statistical analyses 45 -- 4.5 RESULTS 46 -- 4.5.1 Selection of prescribers and patients 46 -- 4.5.2 Choice between high price/low cost drugs 46 -- 4.5.3 Socioeconomic characteristics of patients or physicians and therapeutic reference -- pricing: evidence in the literature 57 -- 4.5.4 Choice of a less costly active ingredient within a class 58 -- 4.5.5 Appraisal of results: barriers to low cost drugs 62 -- 5 SUMMARY, CONCLUSION AND DISCUSSION 63 -- 6 BIBLIOGRAPHY 66 Link for e-copy: https://doi.org/10.57598/R126B Format of e-copy: PDF (726 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1903 Copies(0)
Status No copy Les systèmes de remboursement des médicaments / Maïté le Polain / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
Les systèmes de remboursement des médicaments : comparaison internationale et recommandations aux décideurs [printed text] / Maïté le Polain, Author ; Margreet Franken, Author ; Marc Koopmanschap, Author ; Irina Cleemput , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - XI, 151 p. : ill. ; A4. - (KCE Reports. Health Services Research (HSR); 147B) .
ISSN : D/2010/10.273/89 : € 0,00
2009-19
Languages : English (eng) Original Language : French (fre)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2009-19 ; Advisory Committees ; Decision Making ; Economics, Pharmaceutical ; Insurance, Health, Reimbursement ; Policy Making ; R147Contents note: LIST OF ABBREVIATIONS 3 -- 1 INTRODUCTION 5 -- 1.1 BACKGROUND 5 -- 1.2 OBJECTIVES 6 -- 1.3 METHODS AND ANALYTICAL FRAMEWORKS 6 -- 1.3.1 The description of the drug reimbursement systems 6 -- 1.3.2 Assessing accountability for reasonableness 8 -- 1.4 KEY CONCEPTS 9 -- 1.5 STRUCTURE OF THE REPORT 10 -- 2 COUNTRY COMPARISON 12 -- 2.1 CONTEXTUAL BACKGROUND 12 -- 2.1.1 Health care system characteristics 12 -- 2.1.2 Health care system and policy objectives 12 -- 2.1.3 Health care funding and pharmaceutical expenditure 13 -- 2.1.4 Pharmaceutical policies 15 -- 2.2 POLICY IMPLEMENTATION LEVEL 18 -- 2.2.1 Objectives of the drug reimbursement system. 18 -- 2.2.2 Establishment of the system 19 -- 2.2.3 Implementation: a positive reimbursement list 24 -- 2.2.4 Accountability: impact assessment 24 -- 2.3 TECHNOLOGY DECISION LEVEL 26 -- 2.3.1 Assessment and appraisal phase 26 -- 2.3.2 Decision making phase 32 -- 2.3.3 Output and Implementation 36 -- 3 DISCUSSION 39 -- 3.1 ACCOUNTABILITY FOR REASONABLENESS 39 -- 3.1.1 Transparency 40 -- 3.1.2 Relevance of the decision rationales 41 -- 3.1.3 Relevance of the decision criteria 41 -- 3.1.4 Relevance of decision criteria: summarising countries’ achievements 52 -- 3.1.5 Revisability 53 -- 3.1.6 Enforcement 53 -- 4 GENERAL CONCLUSIONS AND RECOMMENDATIONS 55 -- 4.1 TRANSPARENCY CONDITION 55 -- 4.2 RELEVANCE CONDITION 56 -- 4.3 REVISABILITY CONDITION 57 -- 4.4 ENFORCEMENT CONDITION 57 -- 4.5 FUTURE RESEARCH 57 -- 5 LESSONS FOR BELGIUM 60 -- 5.1 ROLES OF THE DIFFERENT ACTORS IN THE PROCESS 60 -- 5.2 STRENGTHS OF THE BELGIAN REIMBURSEMENT SYSTEM 61 -- 5.3 ISSUES RELATED TO THE DECISION PROCESS 61 -- 5.3.1 Composition of the CRM/CTG 61 -- 5.3.2 Assessment by the RIZIV/INAMI experts 62 -- 5.3.3 Appraisal by the Drug Reimbursement Committee (CRM/CTG) 63 -- 5.3.4 Price and reimbursement basis 64 -- 5.3.5 Reimbursement category 65 -- 5.3.6 Decision by the Minister 66 -- 5.4 DISCUSSION 67 -- 5.4.1 Transparency 67 -- 5.4.2 Relevance of the appraisal criteria 68 -- 5.4.3 Revisions 68 -- 5.5 CONCLUSION 68 -- 6 APPENDICES 69 -- DRUG REIMBURSEMENT SYSTEM IN AUSTRIA 69 -- DRUG REIMBURSEMENT SYSTEM IN BELGIUM 81 -- DRUG REIMBURSEMENT SYSTEM IN FRANCE 99 -- DRUG REIMBURSEMENT SYSTEM IN THE NETHERLANDS 114 -- DRUG REIMBURSEMENT SYSTEM IN SWEDEN 128 -- 7 REFERENCES 143 Link for e-copy: https://doi.org/10.57598/R147B Format of e-copy: PDF (1,24 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2298 Copies(0)
Status No copy Terugbetalingssystemen voor geneesmiddelen / Maïté le Polain / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
Terugbetalingssystemen voor geneesmiddelen : internationale vergelijking en beleidsaanbevelingen [printed text] / Maïté le Polain, Author ; Margreet Franken, Author ; Marc Koopmanschap, Author ; Irina Cleemput , Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - XI, 151 p. : ill. ; A4. - (KCE Reports. Health Services Research (HSR); 147A) .
ISSN : D/2010/10.273/88 : € 0,00
2009-19
Languages : English (eng) Original Language : Dutch (nla)
Descriptors: Classification
QV 736 Drug industry. Economics of pharmacy. Advertising
Indexation
2009-19 ; Advisory Committees ; Decision Making ; Economics, Pharmaceutical ; Insurance, Health, Reimbursement ; Policy Making ; R147Contents note: LIST OF ABBREVIATIONS 3 -- 1 INTRODUCTION 5 -- 1.1 BACKGROUND 5 -- 1.2 OBJECTIVES 6 -- 1.3 METHODS AND ANALYTICAL FRAMEWORKS 6 -- 1.3.1 The description of the drug reimbursement systems 6 -- 1.3.2 Assessing accountability for reasonableness 8 -- 1.4 KEY CONCEPTS 9 -- 1.5 STRUCTURE OF THE REPORT 10 -- 2 COUNTRY COMPARISON 12 -- 2.1 CONTEXTUAL BACKGROUND 12 -- 2.1.1 Health care system characteristics 12 -- 2.1.2 Health care system and policy objectives 12 -- 2.1.3 Health care funding and pharmaceutical expenditure 13 -- 2.1.4 Pharmaceutical policies 15 -- 2.2 POLICY IMPLEMENTATION LEVEL 18 -- 2.2.1 Objectives of the drug reimbursement system. 18 -- 2.2.2 Establishment of the system 19 -- 2.2.3 Implementation: a positive reimbursement list 24 -- 2.2.4 Accountability: impact assessment 24 -- 2.3 TECHNOLOGY DECISION LEVEL 26 -- 2.3.1 Assessment and appraisal phase 26 -- 2.3.2 Decision making phase 32 -- 2.3.3 Output and Implementation 36 -- 3 DISCUSSION 39 -- 3.1 ACCOUNTABILITY FOR REASONABLENESS 39 -- 3.1.1 Transparency 40 -- 3.1.2 Relevance of the decision rationales 41 -- 3.1.3 Relevance of the decision criteria 41 -- 3.1.4 Relevance of decision criteria: summarising countries’ achievements 52 -- 3.1.5 Revisability 53 -- 3.1.6 Enforcement 53 -- 4 GENERAL CONCLUSIONS AND RECOMMENDATIONS 55 -- 4.1 TRANSPARENCY CONDITION 55 -- 4.2 RELEVANCE CONDITION 56 -- 4.3 REVISABILITY CONDITION 57 -- 4.4 ENFORCEMENT CONDITION 57 -- 4.5 FUTURE RESEARCH 57 -- 5 LESSONS FOR BELGIUM 60 -- 5.1 ROLES OF THE DIFFERENT ACTORS IN THE PROCESS 60 -- 5.2 STRENGTHS OF THE BELGIAN REIMBURSEMENT SYSTEM 61 -- 5.3 ISSUES RELATED TO THE DECISION PROCESS 61 -- 5.3.1 Composition of the CRM/CTG 61 -- 5.3.2 Assessment by the RIZIV/INAMI experts 62 -- 5.3.3 Appraisal by the Drug Reimbursement Committee (CRM/CTG) 63 -- 5.3.4 Price and reimbursement basis 64 -- 5.3.5 Reimbursement category 65 -- 5.3.6 Decision by the Minister 66 -- 5.4 DISCUSSION 67 -- 5.4.1 Transparency 67 -- 5.4.2 Relevance of the appraisal criteria 68 -- 5.4.3 Revisions 68 -- 5.5 CONCLUSION 68 -- 6 APPENDICES 69 -- DRUG REIMBURSEMENT SYSTEM IN AUSTRIA 69 -- DRUG REIMBURSEMENT SYSTEM IN BELGIUM 81 -- DRUG REIMBURSEMENT SYSTEM IN FRANCE 99 -- DRUG REIMBURSEMENT SYSTEM IN THE NETHERLANDS 114 -- DRUG REIMBURSEMENT SYSTEM IN SWEDEN 128 -- 7 REFERENCES 143 Link for e-copy: https://doi.org/10.57598/R147A Format of e-copy: PDF (1,23 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2299 Copies(0)
Status No copy The public financing of pharmaceuticals / Jaume Puig-Junoy / Cheltenham, UK ; Northampton, MA : Edward Elgar (2005)
PermalinkThe reference price system and socioeconomic differences in the use of low cost drugs / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkThe reference price system and socioeconomic differences in the use of low cost drugs / France Vrijens / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
PermalinkToekomstscenario’s voor de ontwikkeling en prijszetting van geneesmiddelen / Philippe Vandenbroeck / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2016)
PermalinkValeur en termes de données probantes des informations écrites de l'industrie pharmaceutique destinées aux médecins généralistes / Annelies Van Linden / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)
PermalinkVoorlopige richtlijnen voor farmaco-economisch onderzoek in België / Irina Cleemput / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
Permalink